{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:54:42Z","timestamp":1771484082273,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2657-7","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T13:24:09Z","timestamp":1471008249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib"],"prefix":"10.1186","volume":"16","author":[{"given":"A.","family":"Maleka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"\u00c5str\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"issue":"5","key":"2657_CR1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/107327480401100505","volume":"11","author":"S Brownstein","year":"2004","unstructured":"Brownstein S. Malignant melanoma of the conjunctiva. Cancer Control. 2004;11(5):310\u20136.","journal-title":"Cancer Control"},{"issue":"20","key":"2657_CR2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"2657_CR3","first-page":"241","volume":"223","author":"JM Ko","year":"2011","unstructured":"Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol. 2011;223(2):241\u201350.","journal-title":"J Pathol"},{"issue":"7","key":"2657_CR4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4065\/83.7.825","volume":"83","author":"A Sekulic","year":"2008","unstructured":"Sekulic A, Haluska Jr P, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83(7):825\u201346.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2657_CR5","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","volume":"19","author":"KG Griewank","year":"2013","unstructured":"Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19(12):3143\u201352.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2657_CR6","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1167\/iovs.10-6934","volume":"52","author":"SL Lake","year":"2011","unstructured":"Lake SL, Jmor F, Dopierala J, Taktak AF, Coupland SE, Damato BE. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci. 2011;52(8):5598\u2013604.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"2657_CR7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00008390-200412000-00003","volume":"14","author":"HE Spendlove","year":"2004","unstructured":"Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14(6):449\u201352.","journal-title":"Melanoma Res"},{"issue":"26","key":"2657_CR8","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Minor D, Ribas A, Lebbe C, O\u2019Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205\u201311.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2657_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2657_CR10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CMR.0b013e32832ccd09","volume":"20","author":"H Populo","year":"2010","unstructured":"Populo H, Soares P, Rocha AS, Silva P, Lopes JM. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res. 2010;20(2):107\u201317.","journal-title":"Melanoma Res"},{"issue":"6","key":"2657_CR11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/bjo.73.6.476","volume":"73","author":"DH Char","year":"1989","unstructured":"Char DH, Gragoudas ES, Phillips TL. Uveal melanoma management. Br J Ophthalmol. 1989;73(6):476\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2657_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1755-3768.2008.01369.x","volume":"87","author":"E Kujala","year":"2009","unstructured":"Kujala E, Tuomaala S, Eskelin S, Kivela T. Mortality after uveal and conjunctival melanoma: which tumour is more deadly? Acta Ophthalmol. 2009;87(2):149\u201353.","journal-title":"Acta Ophthalmol"},{"issue":"6892","key":"2657_CR13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"26","key":"2657_CR14","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"9","key":"2657_CR15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809\u201319.","journal-title":"N Engl J Med"},{"issue":"8","key":"2657_CR16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707\u201314.","journal-title":"N Engl J Med"},{"issue":"3","key":"2657_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014;50(3):611\u201321.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2657_CR18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","volume":"3","author":"MR Girotti","year":"2013","unstructured":"Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013;3(2):158\u201367.","journal-title":"Cancer Discov"},{"issue":"7287","key":"2657_CR19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427\u201330.","journal-title":"Nature"},{"issue":"1","key":"2657_CR20","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","volume":"7","author":"M Yancovitz","year":"2012","unstructured":"Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One. 2012;7(1):e29336.","journal-title":"PLoS One"},{"issue":"3","key":"2657_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cmr.0000130006.46885.a0","volume":"14","author":"E Kilic","year":"2004","unstructured":"Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, et al. The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res. 2004;14(3):203\u20135.","journal-title":"Melanoma Res"},{"issue":"8","key":"2657_CR22","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2016.42","volume":"114","author":"A Loskog","year":"2016","unstructured":"Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, et al. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016;114(8):872\u201380.","journal-title":"Br J Cancer"},{"issue":"3","key":"2657_CR23","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564.","journal-title":"PLoS One"},{"key":"2657_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12967-015-0716-5","volume":"13","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med. 2015;13:351.","journal-title":"J Transl Med"},{"issue":"11","key":"2657_CR25","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","volume":"24","author":"M Maio","year":"2013","unstructured":"Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24(11):2911\u20135.","journal-title":"Ann Oncol"},{"issue":"3","key":"2657_CR26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","volume":"26","author":"LA Kottschade","year":"2016","unstructured":"Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26(3):300\u20133.","journal-title":"Melanoma Res"},{"issue":"7387","key":"2657_CR27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100\u20133.","journal-title":"Nature"},{"issue":"22","key":"2657_CR28","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1158\/1078-0432.CCR-13-2007","volume":"19","author":"JL Weber","year":"2013","unstructured":"Weber JL, Smalley KS, Sondak VK, Gibney GT. Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res. 2013;19(22):6329\u201330.","journal-title":"Clin Cancer Res"},{"key":"2657_CR29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/bjophthalmol-2014-305730","volume":"99","author":"X Sheng","year":"2015","unstructured":"Sheng X, Li S, Chi Z, Si L, Cui C, Mao L, et al. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. Br J Ophthalmol. 2015;99:990\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"22","key":"2657_CR30","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1158\/1078-0432.CCR-13-2368","volume":"19","author":"KG Griewank","year":"2013","unstructured":"Griewank KG, Westekemper H, Schilling B, Livingstone E, Schimming T, Sucker A, et al. Conjunctival melanomas harbor BRAF and NRAS mutations--response. Clin Cancer Res. 2013;19(22):6331\u20132.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2657-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T13:40:47Z","timestamp":1568295647000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2657-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2657"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2657-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]},"article-number":"634"}}